The Role of Adipose Triglyceride Lipase and Cytosolic Lipolysis in Cardiac Function and Heart Failure

Heart failure is one of the leading causes of death worldwide. New therapeutic concepts are urgently required to lower the burden of heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF), the two major forms of heart failure. Lipolytic proces...

Full description

Saved in:
Bibliographic Details
Published in:Cell reports. Medicine 2020-04, Vol.1 (1), p.100001-100001, Article 100001
Main Authors: Kintscher, Ulrich, Foryst-Ludwig, Anna, Haemmerle, Guenter, Zechner, Rudolf
Format: Article
Language:English
Subjects:
Acyltransferases - physiology
Cytosol - metabolism
Heart - physiology
Heart Failure - metabolism
Heart Failure - physiopathology
Humans
Lipolysis - genetics
Lipolysis - physiology
Myocardium - metabolism
Review
Stroke Volume - physiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Heart failure is one of the leading causes of death worldwide. New therapeutic concepts are urgently required to lower the burden of heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF), the two major forms of heart failure. Lipolytic processes are induced during the development of heart failure and occur in adipose tissue and multiple organs, including the heart. Increasing evidence suggests that cellular lipolysis, in particular, adipose triglyceride lipase (ATGL) activity, has an important function in cardiac (patho)physiology. This review summarizes the crucial role of cellular lipolysis for normal cardiac function and for the development of HFrEF and HFpEF. We discuss the most relevant pre-clinical studies and elaborate on the cardiac consequences of non-myocardial and myocardial lipolysis modulation. Finally, we critically analyze the therapeutic importance of pharmacological ATGL inhibition as a potential treatment option for HFrEF and/or HFpEF in the future. Cytosolic lipolysis is induced during heart failure, and adipose triglyceride lipase (ATGL) regulates cardiac function. Kintscher et al. discuss how the deletion or inhibition of adipose tissue ATGL improves cardiac function in pre-clinical heart failure models. Pharmacological inhibition of adipose tissue ATGL may provide a therapeutic intervention direction for heart failure.
ISSN:2666-3791
2666-3791
DOI:10.1016/j.xcrm.2020.100001